Afuco™ Anti-Human MMP9 ADCC Therapeutic Antibody (GS-5745), ADCC Enhanced
Anti-MMP9 ADCC Enhanced Antibody (GS-5745) is an ADCC enhanced antibody produced by our Afuco™ platform. GS-5745 is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. Inhibiting MMP9 is expected to block paracrine signaling and metastasis and to alter the immune environment within the tumor. Preliminary safety data demonstrate a manageable safety profile for GS-5745 alone and in combination with chemotherapy. The study has been expanded to enroll additional subjects with pancreatic and esophagogastric cancer to identify potential pharmacodynamic and predictive biomarkers of response.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-513CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | MMP9 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≤1 year at -20°C. |